Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct 16;9(10):3319.
doi: 10.3390/jcm9103319.

Therapeutic Maintenance of Baricitinib and Tofacitinib in Real Life

Valentine Deprez  1 , Laure Le Monnier  1 , Jean-Marc Sobhy-Danial  1 , Franck Grados  1 , Isabelle Henry-Desailly  1 , Sarah Salomon-Goëb  1 , Thibault Rabin  1 , Sanja Ristic  1 , Mathurin Fumery  2 , Patrice Fardellone  1 , Vincent Goëb  1
Affiliations

Therapeutic Maintenance of Baricitinib and Tofacitinib in Real Life

Valentine Deprez et al. J Clin Med. .

Abstract

Background: Janus kinase inhibitors (JAKis) represent a new alternative to treat rheumatoid arthritis (RA). The objective of this study was to evaluate the effectiveness, tolerance profile, and maintenance of these treatments (tofacitinib and baricitinib) in real life.

Methods: All patients in the rheumatology department of Amiens University Hospital treated by JAKis for RA were included from 1 October 2017 to 20 May 2020. Clinical and biological data were provided retrospectively in this observational and single-center study. We aimed to study the JAKi maintenance rate at 12 months and their clinical and biological safety profiles.

Results: Fifty-five patients were included. Drug maintenance at 12 months was 67.6%. Factors associated with poorer maintenance were a higher Charlson comorbidity index (HR 1.311 (1.089-1.579); p = 0.0042), a higher age (HR 1.055 (1.015-1.096); p = 0.0067), and corticosteroids therapy at initiation (HR 2.722 (1.006-7.365); p = 0.0487). The clinical and biological safety profile was generally good.

Conclusions: Our study found that a higher Charlson index, age, and corticosteroids appeared to be associated with the earlier discontinuation of treatment. JAKis had a response and tolerance profile in real life at least equivalent to that of biological disease-modifying antirheumatic drugs (bDMARDs).

Keywords: JAK inhibitors; baricitinib; rheumatoid arthritis; therapeutic maintenance; tofacitinib.

PubMed Disclaimer

Conflict of interest statement

Vincent Goëb has received consulting fees from Abbvie, Lilly, Novartis, Pfizer and Sanofi. Patrice Fardellone has received consulting fees fom AMGEN and UCB. Mathurin Fumery has received consultant fees for Abbvie, Ferring, MSD, Tillots, Janssen, Takeda, Celgene, Gilead, Biogen, Pfizer and Boehringer. Laure Le Monnier has received consulting fees from Novartis. Sarah Salomon-Goëb has received consulting fees from Pfizer. Franck Grados has received grants from Lilly for his participation at French Society of Rheumatology congress. Sanja Ristic has received consulting fees from Novartis. Valentine Deprez, Jean-Marc Sobhy-Danial, Isabelle Henry-Desailly and Thibault Rabin, declare that they have no conflict of interest.

Figures

Figure 1
Figure 1
Janus kinase inhibitor maintenance in time.
Figure 2
Figure 2
European League against Rheumatism (EULAR) response variation on DAS-28 ESR.
Figure 3
Figure 3
EULAR response variation on DAS-28 CRP.
Figure 4
Figure 4
Clinical parameter variation. VAS: Visual Analog Scale.
See this image and copyright information in PMC

References

    1. Smolen J.S., Aletaha D., McInnes I.B. Rheumatoid arthritis. Lancet. 2016;388:2023–2038. doi: 10.1016/S0140-6736(16)30173-8. - DOI - PubMed
    1. Malemud C.J. The role of the JAK/STAT signal pathway in rheumatoid arthritis. Ther. Adv. Musculoskelet Dis. 2018;10:117–127. doi: 10.1177/1759720X18776224. - DOI - PMC - PubMed
    1. Dowty M.E., Lin T.H., Jesson M.I., Hegen M., Martin D.A., Katkade V., Menon S., Telliez J. Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition. Pharmacol. Res. Perspect. 2019;7 doi: 10.1002/prp2.537. - DOI - PMC - PubMed
    1. Smolen J.S., Landewé R.B.M., Bijlsma J.W.J., Burmester G.R., Dougados M., Kerschbaumer A., McInnes I.B., Sepriano A., van Vollenhoven R.F., de Wit M., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann. Rheum. Dis. 2020 doi: 10.1136/annrheumdis-2019-216655. - DOI - PubMed
    1. Walker J.G., Ahern M.J., Coleman M., Weedon H., Papangelis V., Beroukas D., Roberts-Thomson P.J., Smith M.D. Changes in synovial tissue Jak-STAT expression in rheumatoid arthritis in response to successful DMARD treatment. Ann. Rheum. Dis. 2006;65:1558–1564. doi: 10.1136/ard.2005.050385. - DOI - PMC - PubMed

LinkOut - more resources